AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D) ...

AstraZeneca's strategic $50B investment promises to revolutionize U.S. medicine production with advanced manufacturing and ...

The money will focus on a manufacturing plant in Virginia that will make the company's weight management and metabolic drugs ...

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...

The company plans to invest billions in a new drug manufacturing hub in Virginia, dedicated to chronic disease treatments, alongside additional facilities in California, Indiana, Maryland, ...

AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of ...

AstraZeneca to invest $50 billion in America for medicines manufacturing and R&D: Cambridge, UK Wednesday, July 23, 2025, 09:00 Hrs [IST] AstraZeneca announces $50 billion of inve ...

AstraZeneca (AZ) has become the latest major drugmaker to announce a significant investment in the US, committing $50bn into ...

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and ...